

MAR 11 2004

**In the United States Patent and Trademark Office**

Appl. No.: 10/070,039 Confirmation No. 9715  
Applicant(s): Alonso-Alija, et al.  
Filed: 10/22/2002  
TC/A.U.: 1625  
Examiner: Reyes, Hector M.  
  
Docket No.: Le A 33 893  
Customer No.: 35969

**CERTIFICATION OF TRANSMISSION UNDER 37 C.F.R. 1.8**

I hereby certify that this correspondence, and any papers referred to in this certificate as being attached, are being facsimile transmitted to the United States Patent and Trademark Office on the date shown below.

Date: 11 March 2005

  
William F. Gray**RESPONSE TO RESTRICTION / ELECTION OF SPECIES REQUIREMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


Sir:

This is in response to the Office Action dated 01/11/2005. Please amend the above-identified application as follows:

Remarks begin on page 2 of this paper.

Remarks

In response to the restriction and election of species requirements, applicants elect to proceed with prosecution of restriction group II and elects the species of example 72 (page 168). The structure of example 72 is as follows:



In accordance with the examiner's offer to rejoin a method of using the elected compounds in treatment of a specific disease, applicants choose hypertension as the disease to be considered.

Claims 1-4, 6-9, and 12-20 are deemed to read on the elected species.

Respectfully submitted,

Reg. No. 31018  
Phone: (203) 812-2712  
Date: 11 March 2005

William F. Gray  
William F. Gray  
Bayer Pharmaceuticals Corporation  
400 Morgan Lane  
West Haven, CT 06516-4175